The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA

被引:122
作者
Baxter, EJ
Hochhaus, A
Bolufer, P
Reiter, A
Fernandez, JM
Senent, L
Cervera, J
Moscardo, F
Sanz, MA
Cross, NCP [1 ]
机构
[1] Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England
[2] Univ Southampton, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England
[3] Klinikum Mannheim, Med Univ Klin 3, D-68305 Mannheim, Germany
[4] Hosp Univ La Fe, Dept Med Biopathol, Valencia 46009, Spain
[5] Hosp Univ La Fe, Hematol Serv, Valencia 46009, Spain
关键词
D O I
10.1093/hmg/11.12.1391
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic myeloid leukaemia (CML) is characterized by the presence of the BCR-ABL fusion gene, usually in association with the t(9;22)(q34;q11) translocation. We report here the identification and cloning of a rare variant translocation, t(4;22)(q12;q11), in two patients with a CML-like myeloproliferative disease (MPD). RT-PCR indicated that both patients were negative for BCR-ABL, but FISH analysis suggested that the BCR gene was rearranged. Since other translocations in MPDs frequently involve tyrosine kinases, we designed a multiplex PCR to search for mRNA fusions between BCR and three potential partner genes at 4q12: KIT, KDR and PDGFRA. An unusual inframe BCR-PDGFRA fusion mRNA was identified in both patients, with either BCR exon 7 or exon 12 fused to short BCR intron-derived sequences, which were in turn fused to part of PDGFRA exon 12. Sequencing of the genomic breakpoint junctions showed that the chromosome 22 breakpoints fell in BCR introns whereas the chromosome 4 breakpoints were within PDGFRA exon 12. This is the first report of a fusion gene that involves PDGFRA. Our findings indicate that apparently simple cytogenetic variants of t(9;22) do not always mask a cryptic BCR-ABL fusion, even when found in association with clinical and haematological indications of CML.
引用
收藏
页码:1391 / 1397
页数:7
相关论文
共 26 条
[1]  
APPERLEY JF, 2002, UNPUB CHRONIC MYELOP
[2]   The TEL platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways [J].
Carroll, M ;
Tomasson, MH ;
Barker, GF ;
Golub, TR ;
Gilliland, DG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14845-14850
[3]   CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].
Carroll, M ;
OhnoJones, S ;
Tamura, S ;
Buchdunger, E ;
Zimmermann, J ;
Lydon, NB ;
Gilliland, DG ;
Druker, BJ .
BLOOD, 1997, 90 (12) :4947-4952
[4]  
CHASE A, 2001, CYTOGENETICS HAE 1 3, V4, P553
[5]   Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12) (q11-q12;p13) [J].
Cools, J ;
Bilhou-Nabera, C ;
Wlodarska, I ;
Cabrol, C ;
Talmant, P ;
Bernard, P ;
Hagemeijer, A ;
Marynen, P .
BLOOD, 1999, 94 (05) :1820-1824
[6]  
CROSS NCP, 1994, LEUKEMIA, V8, P186
[7]   The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins [J].
Demiroglu, A ;
Steer, EJ ;
Heath, C ;
Taylor, K ;
Bentley, M ;
Allen, SL ;
Koduru, P ;
Brody, JP ;
Hawson, G ;
Rodwell, R ;
Doody, ML ;
Carnicero, F ;
Reiter, A ;
Goldman, JM ;
Melo, JV ;
Cross, NCP .
BLOOD, 2001, 98 (13) :3778-3783
[8]   Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566
[9]   Chronic myeloid leukemia associated hypereosinophilic syndrome with a clonal t(4;7)(q11;q32) [J].
Duell, T ;
Mittermuller, J ;
Schmetzer, HM ;
Kolb, HJ ;
Wilmanns, W .
CANCER GENETICS AND CYTOGENETICS, 1997, 94 (02) :91-94
[10]   INDUCTION OF PLATELET-DERIVED GROWTH-FACTOR-A AND GROWTH-FACTOR-B CHAINS AND OVER-EXPRESSION OF THEIR RECEPTORS IN HUMAN PANCREATIC-CANCER [J].
EBERT, M ;
YOKOYAMA, M ;
FRIESS, H ;
KOBRIN, MS ;
BUCHLER, MW ;
KORC, M .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (05) :529-535